19:20 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Eidos raises $106M in IPO priced at top of range

Eidos Therapeutics Inc. (NASDAQ:EIDX) added $6.12 (36%) to $23.12 June 20 after raising $106.3 million through the sale of 6.3 million shares at $17 in an IPO underwritten by J.P. Morgan, BofA Merrill Lynch and...
14:15 , Jun 20, 2018 |  BC Extra  |  Financial News

Eidos gets first-day bump after pricing IPO at top of range

Eidos Therapeutics Inc. (NASDAQ:EIDX) added $6.12 (36%) to $23.12 Wednesday after raising $106.3 million through the sale of 6.3 million shares at $17 in an IPO underwritten by J.P. Morgan, BofA Merrill Lynch and Barclays....
19:16 , Jun 1, 2018 |  BC Week In Review  |  Financial News

Eidos proposes $115M NASDAQ IPO

Eidos Therapeutics Inc. (Palo Alto, Calif.) proposed on May 25 to raise $115 million in an IPO underwritten by J.P. Morgan, BofA Merrill Lynch and Barclays. In April, the company raised $64 million in a series...
22:08 , May 25, 2018 |  BC Extra  |  Financial News

Eidos, Avrobio propose NASDAQ IPOs

Eidos Therapeutics Inc. (Palo Alto, Calif.) and Avrobio Inc. (Cambridge, Mass.) proposed NASDAQ IPOs on Friday. Eidos proposed to raise $115 million in an IPO underwritten by J.P. Morgan, BofA Merrill Lynch and Barclays. Last month,...
17:06 , Apr 6, 2018 |  BC Week In Review  |  Financial News

RA Capital leads Eidos' $64M series B round

Eidos Therapeutics Inc. (San Francisco, Calif.) raised a $64 million series B round led by new investor RA Capital. Eidos' parent company, BridgeBio Pharma LLC (Palo Alto, Calif.), also participated, as did new investors Janus...
15:49 , Apr 5, 2018 |  BC Extra  |  Financial News

RA Capital leads Eidos' $64M series B round

Eidos Therapeutics Inc. (San Francisco, Calif.) raised a $64 million series B round led by new investor RA Capital. Eidos' parent company, BridgeBio Pharma LLC (Palo Alto, Calif.), also participated, as did new investors Janus...
22:12 , Sep 15, 2017 |  BioCentury  |  Finance

Orphan opportunity

Private equity giant KKR returned to co-lead BridgeBio Pharma LLC's $135 million venture round, which could enable the Orphan play to double its pipeline in the next two years. KKR co-led the Sept. 13 round...
20:29 , Sep 15, 2017 |  BC Week In Review  |  Financial News

BridgeBio raises $135M round

On Sept. 13, BridgeBio Pharma (Palo Alto, Calif.) raised $135 million in an undisclosed venture round led by new investor Viking Global Investors and existing investor KKR. New investors AIG, Aisling Capital, Cormorant Capital and Janus...
22:59 , Sep 13, 2017 |  BC Extra  |  Financial News

BridgeBio raises $135M round

BridgeBio Pharma (Palo Alto, Calif.) raised $135 million in an undisclosed venture round led by new investor Viking Global Investors and existing investor KKR. New investors AIG, Aisling Capital, Cormorant Capital and Janus Funds also...
00:21 , Apr 29, 2017 |  BioCentury  |  Finance

Coming out party

With the announcement of a $27 million commitment to its Eidos Therapeutics Inc. subsidiary, two-year-old BridgeBio Pharma is beginning to lift the veil on its portfolio of rare genetic disease plays. Eidos, which is developing transthyretin...